Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Antibe Therapeutics (ATBPF)

Antibe Therapeutics (ATBPF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 88,720
  • Shares Outstanding, K 280,937
  • Annual Sales, $ 7,270 K
  • Annual Income, $ -9,770 K
  • 60-Month Beta -0.36
  • Price/Sales 12.15
  • Price/Cash Flow N/A
  • Price/Book 19.16
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 12/20/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2778 +13.68%
on 12/02/19
0.3335 -5.31%
on 11/26/19
-0.0022 (-0.69%)
since 11/13/19
3-Month
0.2761 +14.38%
on 09/30/19
0.4100 -22.98%
on 10/30/19
+0.0280 (+9.73%)
since 09/13/19
52-Week
0.1800 +75.44%
on 12/18/18
0.4100 -22.98%
on 10/30/19
+0.1303 (+70.24%)
since 12/13/18

Most Recent Stories

More News
Antibe Therapeutics Provides Corporate Update and Reports Q2 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Reports Q1 2020 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, August 27th for the fiscal quarter ended June 30, 2019. The Company's...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Provides Update on Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today provides an update on the Phase 2B dose-ranging,...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Announces Closing of Public Offering

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that is has closed its previously announced...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Announces Filing of Final Short Form Prospectus

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE), a leader in developing safer therapeutics for pain and inflammation, announces that it has filed a final short form prospectus (the "Final...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Announces Size of Offering

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, announces that its previously-announced marketed offering...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Announces Offering of Units

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer therapeutics for pain and inflammation, today announced that it has filed a preliminary short...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Reports 2019 Year-End Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV:ATE, OTCQB:ATBPF) filed its financial and operating results on Tuesday, July 16 for the fourth quarter and the year ended March 31, 2019. The...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Announces Results of Annual General and Special Meeting

Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the results of its annual general and special meeting held earlier today. All resolutions outlined...

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)
Antibe Therapeutics Announces CEO Letter to Shareholders

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF):

ATBPF : 0.3158 (+0.41%)
ATE.VN : 0.425 (+3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade ATBPF with:

Key Turning Points

2nd Resistance Point 0.3215
1st Resistance Point 0.3187
Last Price 0.3158
1st Support Level 0.3138
2nd Support Level 0.3117

See More

52-Week High 0.4100
Fibonacci 61.8% 0.3221
Last Price 0.3158
Fibonacci 50% 0.2950
Fibonacci 38.2% 0.2679
52-Week Low 0.1800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar